CClinicalTrials.gg
CompletedNCT05431218COPDUpdated Apr 12, 2024

Association of Cathelicidin and Vitamin D Levels With the Category and Course of COPD

A Phase 4 interventional study of Cholecalciferol Liquid in Chronic Obstructive Pulmonary Disease, Chronic Obstructive Pulmonary Disease Moderate and Chronic Obstructive Pulmonary Disease Severe, sponsored by Karaganda Medical University. Completed at 1 site in Kazakhstan. Open to participants aged 18 Years to 84 Years. Per ClinicalTrials.gov, last updated 2024-04-12.

Sponsored by Karaganda Medical University · Phase 4, Interventional, and Supportive care

From the registry’s dates

  • Registered 2 years 3 months after the study started (first participant enrolled Feb 2020, registered May 2022).
Phase
Phase 4
Study type
Interventional
Enrollment
120
Allocation
Non-randomized
Ages
18 Years to 84 Years
Sex
All
01

Study summary

Recruitment of patients with COPD. Assessment of clinical status, determination of vitamin D and cathelicidin levels. In the group with vitamin D deficiency, patients receive cholecalciferol (vitamin D) daily for 3 months. After 3 months, the clinical status was assessed again, the level of vitamin D and cathelicidin was determined. When vitamin D levels normalize, cholecalciferol replacement therapy is discontinued for 3 months. After that, a control inspection and laboratory tests are performed.

Read the detailed description

Interventional prospective research design.

The study will be conducted on patients with moderate and severe COPD. The material for the study will be the blood and sputum of patients with COPD.

Research methods: biochemical, enzyme immunoassay, bacteriological, radiological, spirography, clinical, statistical analysis.

The recruitment of patients is carried out in the pulmonology department of the hospital according to the inclusion and exclusion criteria. Patient participation is voluntary. First, the patient is told about the study. If he agrees, he signs an informed consent to conduct research.

Clinical examination of the patient, anthropometry, standard COPD assessment tests will be conducted in the hospital.

Laboratory tests will be conducted in medical institutions in Karaganda and will include a detailed general blood test, determination of fibrinogen and CRP (C-reactive protein) levels, general sputum analysis and bacteriological sputum examination.

Instrumental studies are carried out in medical institutions of the city: spirometry (determination of FEV1 (forced exhalation volume), Gensler index and Tiffno), lung radiography.

The study of vitamin D and cathelicidin is carried out by the ELISA method in the laboratory of the Medical University. Assessment of vitamin D status will be carried out by determining the level of total 25(OH)D (circulating serum, total D2 and D3) with verification of the method relative to international standards (National Institute of Standards and Technology - National Institute of Standards and Technology (NIST), Vitamin D External Quality Assessment Scheme (DEQAS)). The interpretation of vitamin D levels will be carried out according to international standards:

less than 10 ng/ml severe deficiency; 10-20 ng/ml moderate deficiency; 20-30 ng/ml mild deficiency; 30-100 ng/ml Norm; more than 100 ng/ml toxic level.

Quantitative determination of the level of antimicrobial peptide cathelicidin (LL-37) in blood serum will be carried out using enzyme immunoassay (NK321, HumanLL-37 ELISA Kit, Hycult biotech, the Netherlands) in accordance with the manufacturer's instructions. . Normal levels of LL-37: 50-80 ng/ml.

Among the patients with COPD selected at the outpatient stage, persons with vitamin 25(OH) deficiency were identifiedD in the blood (insufficiency/deficiency). In this group, patients received a therapeutic dose of an aqueous solution of cholecalciferol for three months. The therapeutic dose of an aqueous solution of cholecalciferol will be calculated individually according to clinical recommendations for the treatment of vitamin D deficiency and insufficiency.

Patients will continue treatment of the underlying COPD disease according to the clinical protocol. Vitamin therapy is an addition to the main treatment, it should strengthen the immunity and protective abilities of the body. After three months of replacement therapy with cholecalciferol and the next 3 months without it, clinical, laboratory and instrumental research methods will be repeated to assess the effectiveness.

Statistical processing of the research results is supposed to be carried out using statistical packages Excel 2010 (Microsoft, USA), Statistica 10.0 (StatSoft, Inc., USA). Methods of parametric and nonparametric statistics will be used: Student's criterion (t), Mann-Whitney (U), Wilcoxon; correlation analysis with calculation of Spearman's correlation coefficient (R). To compare the case-control groups with a quantitative assessment of the relationship between the factor and the outcome, the odds ratio (OR) with 95% CI will be calculated.

02

Conditions studied

  • Chronic Obstructive Pulmonary Disease
  • Chronic Obstructive Pulmonary Disease Moderate
  • Chronic Obstructive Pulmonary Disease Severe

Keywords

  • COPD
  • vitamin D
  • cathelicidin
  • antimicrobial peptide
03

In context

Lung Diseases

3,303 studies on the registry are indexed under Lung Diseases; 355 are open to participants now.

This study's enrollment of 120 is above the median of 72 across 2,118 interventional studies indexed under Lung Diseases.

Browse Lung Diseases studies →

Lead sponsor

Karaganda Medical University is the lead sponsor of 10 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 84 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Clinically confirmed chronic obstructive pulmonary disease

Exclusion criteria

Exclusion Criteria:

  • age under 18
  • pregnancy
  • mental disorders
  • cancer
  • terminal renal and hepatic insufficiency
05

Study design

Phase
Phase 4
Primary purpose
Supportive care
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
120 participants (actual)

Study arms

  • No intervention
    normal vitamin D levels

    Patients with normal vitamin D levels (30-100ng/ml) No interference is implied. Observation only

  • Active comparator
    Mild vitamin D deficiency

    Patients with mild vitamin D deficiency (20-29 ng/ml)They will receive 4000 IU of cholecalciferol per day for 3 months

    Drug: Cholecalciferol Liquid

  • Active comparator
    Moderate vitamin D deficiency

    Patients with moderate vitamin D deficiency (10-19 ng/ml) will receive cholecalciferol at a dose of 5000-6000 IU daily for 3 months

    Drug: Cholecalciferol Liquid

  • Active comparator
    Severe vitamin D deficiency

    Patients with moderate vitamin D deficiency (10-19 ng/ml) will receive cholecalciferol at a dose of 7000-8000 IU daily for 3 months

    Drug: Cholecalciferol Liquid

Interventions

  • DrugCholecalciferol Liquid

    daily single dose of the drug in the first half of the day in an individually selected dose for 3 months

    Also known as: D vitamin

06

What researchers measure

Primary outcomes

  1. Dynamics of vitamin D levels at baseline and 3 months

    Assessment of the levels of vitamin D (ng / ml) in blood plasma and evaluate the dynamics of the measurement of the indicator in the same patient in different periods of time, and compare the indicators in groups of patients

    Time frame: At baseline and 3 months

  2. Dynamics of vitamin D levels at baseline and 6 months

    Assessment of the levels of vitamin D (ng / ml) in blood plasma and evaluate the dynamics of the measurement of the indicator in the same patient in different periods of time, and compare the indicators in groups of patients

    Time frame: At baseline and 6 months

  3. Dynamics of vitamin D levels at 3 months and 6 months

    Assessment of the levels of vitamin D (ng / ml) in blood plasma and evaluate the dynamics of the measurement of the indicator in the same patient in different periods of time, and compare the indicators in groups of patients

    Time frame: At 3 months and 6 months

  4. Dynamics of cathelicidin levels at baseline and 3 months

    Assessment of cathelicidin levels (ng / ml) in blood plasma and and evaluate the dynamics of the measurement of the indicator in the same patient in different periods of time, and compare the indicators in groups of patients

    Time frame: At baseline and 3 months

  5. Dynamics of cathelicidin levels at baseline and 6 months

    Assessment of cathelicidin levels (ng / ml) in blood plasma and and evaluate the dynamics of the measurement of the indicator in the same patient in different periods of time, and compare the indicators in groups of patients

    Time frame: At baseline and 6 months

  6. Dynamics of cathelicidin levels at 3 months and 6 months

    Assessment of cathelicidin levels (ng / ml) in blood plasma and evaluate the dynamics of the measurement of the indicator in the same patient in different periods of time, and compare the indicators in groups of patients

    Time frame: At 3 months and 6 months

07

Study locations

1 site
  • Karaganda Medical University
    Karaganda, 100000, Kazakhstan
08

References and documents

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05431218
Lead sponsor
Karaganda Medical University
Responsible party
Sponsor
First posted
Jun 24, 2022
Start date
Feb 18, 2020
Primary completion
Dec 30, 2021
Completion
Dec 31, 2021
Last update
Apr 12, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion